Abstract

Introduction

The aim of this study was to evaluate the impact of the contouring methods on dose metrics and their predictive value on tumor control and survival, in both situations of pre-treatment and post-treatment dosimetry, for patients with advanced HCC treated with SIRT.

Methods

Forty-eight patients who underwent SIRT between 2012 and 2020 were retrospectively included in this study. Target volumes were delineated using two methods: MRI-based contours manually drawn by a radiologist and then registered on SPECT/CT and PET/CT via deformable registration (Pre-CMRI and Post-CMRI), 99mTc-MAA-SPECT and 90Y-microspheres-PET 10% threshold contouring (Pre-CSPECT and Post-CPET). The mean absorbed dose (Dm) and the minimal absorbed dose delivered to 70% of the tumor volume (D70) were evaluated with both contouring methods; the tumor-to-normal liver uptake ratio (TNR) was evaluated with MRI-based contours only. Tumor response was assessed using the mRECIST criteria on the follow-up MRIs.

Results

No significant differences were found for Dm and TNR between pre- and post-treatment. TNR evaluated with radiologic contours (Pre-CMRI and Post-CMRI) were predictive of tumor control at 6 months on pre- and post-treatment dosimetry (OR 5.9 and 7.1, respectively; p = 0.02 and 0.01). All dose metrics determined with both methods were predictive of overall survival (OS) on pre-treatment dosimetry, but only Dm with MRI-based contours was predictive of OS on post-treatment images with a median of 23 months for patients with a supramedian Dm versus 14 months for the others (p = 0.04).

Conclusion

In advanced HCC treated with SIRT, Dm and TNR determined with radiologic contours were predictive of tumor control and OS. This study shows that a rigorous clinical workflow (radiologic contours + registration on scintigraphic images) is feasible and should be prospectively considered for improving therapeutic strategy.

Details

Title
Impact of contouring methods on pre-treatment and post-treatment dosimetry for the prediction of tumor control and survival in HCC patients treated with selective internal radiation therapy
Author
Nodari Guillaume 1   VIAFID ORCID Logo  ; Popoff Romain 2 ; Riedinger, Jean Marc 1 ; Lopez, Olivier 3 ; Pellegrinelli, Julie 3 ; Dygai-Cochet Inna 1 ; Tabouret-Viaud Claire 1 ; Presles Benoit 4 ; Chevallier Olivier 5 ; Gehin Sophie 3 ; Gallet Matthieu 1 ; Latournerie Marianne 6 ; Manfredi Sylvain 6 ; Loffroy Romaric 5 ; Vrigneaud, Jean Marc 2 ; Cochet Alexandre 2 

 Centre Georges-François Leclerc, Department of Nuclear Medicine, Dijon, France (GRID:grid.418037.9) (ISNI:0000 0004 0641 1257) 
 Centre Georges-François Leclerc, Department of Nuclear Medicine, Dijon, France (GRID:grid.418037.9) (ISNI:0000 0004 0641 1257); University of Burgundy, ImViA Laboratory, IFTIM Team, EA 7535, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313) 
 University Hospital Dijon, Department of Vascular and Interventional Radiology, Dijon, France (GRID:grid.31151.37) 
 University of Burgundy, ImViA Laboratory, IFTIM Team, EA 7535, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313) 
 University of Burgundy, ImViA Laboratory, IFTIM Team, EA 7535, Dijon, France (GRID:grid.5613.1) (ISNI:0000 0001 2298 9313); University Hospital Dijon, Department of Vascular and Interventional Radiology, Dijon, France (GRID:grid.31151.37) 
 University Hospital Dijon, Department of Gastroenterology, Dijon, France (GRID:grid.31151.37) 
Publication year
2021
Publication date
Mar 2021
Publisher
Springer Nature B.V.
e-ISSN
2191219X
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2499223550
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.